Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 11Terminated 4Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Colorectal Neoplasms 77Carcinoma, Hepatocellular 48Ovarian Neoplasms 41Carcinoma, Non-Small-Cell Lung 26Neoplasms 22Fallopian Tube Neoplasms 17Lung Neoplasms 15Breast Neoplasms 13Neoplasm Metastasis 12Glioblastoma 12Endometrial Neoplasms 12Colonic Neoplasms 11Brain Neoplasms 11Uterine Cervical Neoplasms 10Triple Negative Breast Neoplasms 10Rectal Neoplasms 10Liver Neoplasms 9Stomach Neoplasms 8Colorectal Cancer Metastatic 7Pancreatic Neoplasms 6Advanced Solid Tumors 6Recurrence 5Melanoma 5Glioma 5Carcinoma, Renal Cell 5Carcinoma, Ovarian Epithelial 5Biliary Tract Neoplasms 5Solid Tumor 4Meningeal Carcinomatosis 4Adenocarcinoma of Lung 4

Interventions

Doxorubicin 15pembrolizumab 12Cyclophosphamide 9Surgical Procedures, Operative 8Gemcitabine 8Blood Specimen Collection 8Ifosfamide 7Surveys and Questionnaires 6Nivolumab 6Trabectedin 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Drug Therapy 5fludarabine 4Temozolomide 4Specimen Handling 4Radiation Dose Hypofractionation 4Biopsy 4selinexor 3pazopanib 3liposomal doxorubicin 3cabozantinib 3atezolizumab 3anlotinib 3Radiation 3Observation 3Docetaxel 3Dacarbazine 3trastuzumab deruxtecan 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Sarcoma × Bevacizumab × Clear all
NCT03715933 2026-05-22

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Inhibrx Biosciences, Inc

Phase 1 Recruiting
411 enrolled
Sarcoma

Sarcoma, Sarcoma, Ewing

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

GI Innovation, Inc.

Phase 1/2 Recruiting
358 enrolled
DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡